Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza®) and obesity (gSaxenda®), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management.
The launch follows the approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year and will mark the first country in the European Union where the Company will directly launch Liraglutide under its own brand.